Physician profile
Philip Sutherland
NPI 1720083819
$3,116.83
in general payments reported to CMS, 2019-2025
19 companies · $411 in 2025
The $411 reported for 2025 was more than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $391 · 2020: $168 · 2021: $328 · 2022: $579 · 2023: $592 · 2024: $647 · 2025: $411.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,650.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,650.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $803.75 | 2022-2025 | Infuse, Zenlens, Vyzulta |
| Alcon Vision LLC | $382.43 | 2019-2025 | Rocklatan, Simbrinza, Rhopressa |
| Oyster Point Pharma, INC. | $333.13 | 2022-2024 | Tyrvaya, Ryzumvi |
| Aerie Pharmaceuticals, INC. | $263.29 | 2019-2021 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $230.84 | 2019-2021 | |
| Mallinckrodt Hospital Products INC. | $158.84 | 2024-2025 | Acthar |
| Johnson & Johnson Vision Care, INC. | $147.21 | 2019-2022 | |
| Astellas Pharma US INC | $134.34 | 2024-2025 | Izervay |
| Sun Pharmaceutical Industries INC. | $111.52 | 2019-2025 | Cequa |
| Abbvie INC. | $101.72 | 2022-2025 | Alphagan P, Vuity, Lumigan |
| Amgen INC. | $97.69 | 2024-2025 | Tepezza |
| Coopervision INC. | $90.95 | 2019-2025 | Clariti Contact Lens, Myday Contact Lens |
| Horizon Therapeutics Plc | $81.72 | 2022 | |
| Kala Pharmaceuticals, INC. | $46.18 | 2021 | |
| Novartis Pharmaceuticals Corporation | $39.51 | 2019-2021 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Omeros Corporation | $37.56 | 2019-2021 | |
| Glaukos Corporation | $24.90 | 2024 | Idose |
| Rayner Intraocular Lenses Limited | $19.04 | 2023 | Rayone Emv, Rayone Aspheric, Omidria |
| Dompe US, INC. | $12.21 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Philip Sutherland listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.